Clinical comparison and agreement of PCR, antigen, and viral culture for the diagnosis of COVID-19: Clinical Agreement Between Diagnostics for COVID19
dc.contributor.author | Agard, Amanda | |
dc.contributor.author | Elsheikh, Omar | |
dc.contributor.author | Bell, Drew | |
dc.contributor.author | Relich, Ryan F. | |
dc.contributor.author | Schmitt, Bryan H. | |
dc.contributor.author | Sadowski, Josh | |
dc.contributor.author | Fadel, William | |
dc.contributor.author | Webb, Douglas H. | |
dc.contributor.author | Dbeibo, Lana | |
dc.contributor.author | Kelley, Kristen | |
dc.contributor.author | Carozza, Mariel | |
dc.contributor.author | Lei, Guang-Shen | |
dc.contributor.author | Calkins, Paul | |
dc.contributor.author | Beeler, Cole | |
dc.contributor.department | Medicine, School of Medicine | en_US |
dc.date.accessioned | 2023-07-17T15:28:31Z | |
dc.date.available | 2023-07-17T15:28:31Z | |
dc.date.issued | 2022 | |
dc.description.abstract | The aim of this study is to compare the COVID-19 nasopharyngeal PCR (NP PCR) to antigen, nasal PCR, and viral culture. One-hundred-and-fourteen risk-stratified patients were tested by culture, nasal PCR, NP PCR, and Ag testing. Twenty (48%) of the high risk and 23 (32%) of the low risk were NP PCR positive. Compared with NP PCR, the sensitivity of nasal PCR, Sofia Ag, BinaxNOW Ag, and culture were 44%, 31%, 37%, and 15%. In the high risk group, the sensitivity of these tests improved to 71%, 37%, 50%, and 22%. Agreement between tests was highest between nasal PCR and both antigen tests. Patients who were NP PCR positive but antigen negative were more likely to have remote prior COVID-19 infection (p<0.01). Nasal PCR and antigen positive patients were more likely to have symptoms (p = 0.01). | en_US |
dc.eprint.version | Final published version | en_US |
dc.identifier.citation | Agard A, Elsheikh O, Bell D, et al. Clinical comparison and agreement of PCR, antigen, and viral culture for the diagnosis of COVID-19: Clinical Agreement Between Diagnostics for COVID19. J Clin Virol Plus. 2022;2(3):100099. doi:10.1016/j.jcvp.2022.100099 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/34419 | |
dc.language.iso | en_US | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.isversionof | 10.1016/j.jcvp.2022.100099 | en_US |
dc.relation.journal | Journal of Clinical Virology Plus | en_US |
dc.rights | Publisher Policy | en_US |
dc.source | PMC | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | Antigen testing | en_US |
dc.subject | PCR testing | en_US |
dc.subject | Viral culture | en_US |
dc.subject | Diagnostics | en_US |
dc.title | Clinical comparison and agreement of PCR, antigen, and viral culture for the diagnosis of COVID-19: Clinical Agreement Between Diagnostics for COVID19 | en_US |
dc.type | Article | en_US |
ul.alternative.fulltext | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300048/ | en_US |